liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Patient preferences for characteristics differentiating ovarian stimulation treatments
OptumInsight, Stockholm.
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences.
Merck Serono AB, Stockholm.
Karolinska Universitetssjukhuset, Huddinge, Stockholm.
Show others and affiliations
2012 (English)In: Human Reproduction, ISSN 0268-1161, E-ISSN 1460-2350, Vol. 27, no 3, 760-769 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND Little is known concerning patient preferences for IVF treatments. The objective of this study was to elicit patient preferences for characteristics differentiating ovarian stimulation treatments.

METHODS Women undergoing IVF were recruited from six clinics in Sweden between May 2010 and December 2010. Included patients completed a study questionnaire consisting of one contingent valuation (CV) question (with six different bids) and 16 conjoint analysis (CA) questions formulated as discrete choices between two hypothetical ovarian stimulation treatments (defined in terms of manufacturing method, method of administration, time required for administration, dose variability and hypothetical price). Patient preferences were derived using multinomial logit modelling.

RESULTS The final study population consisted of 294 women (mean age of 35). Respondents were willing to pay €360 [95% confidence interval (CI): €340-€390] to receive FSH derived from DNA technology instead of highly purified extract from urine from post-menopausal women, €300 (95% CI: €280-€320) to administer the FSH using a prefilled injection pen instead of a conventional syringe, €30 (95% CI: €20-€40) per saved minute required for administration and €530 (95% CI: €500-€570) to reduce the dose variability from 10-20% to 1-2%(P< 0.001 for all estimates). The result from the CV was similar to the CA.

CONCLUSIONS Women undergoing IVF place significant value on characteristics differentiating ovarian stimulation treatments. Product-specific aspects should be taken into account by decision-makers when discriminating between commercial gonadotrophins in clinical practice to align health-care decision-making with patient preferences and potentially improve the effectiveness of IVF interventions through enhanced patient satisfaction and treatment compliance. Preferences for treatment characteristics should also be considered in evaluations of ovarian stimulation products to capture their true value from a patient perspective.

Place, publisher, year, edition, pages
Oxford University Press (OUP): Policy B1 , 2012. Vol. 27, no 3, 760-769 p.
Keyword [en]
IVF, FSH, contingent valuation, conjoint analysis, Sweden
National Category
Engineering and Technology
URN: urn:nbn:se:liu:diva-76019DOI: 10.1093/humrep/der449ISI: 000300510100018OAI: diva2:512837
Funding Agencies|Merck Serono AB, Stockholm, Sweden||Available from: 2012-03-29 Created: 2012-03-23 Last updated: 2012-04-04

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Jablonowska, Barbara
By organisation
Department of Clinical and Experimental MedicineFaculty of Health Sciences
In the same journal
Human Reproduction
Engineering and Technology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 61 hits
ReferencesLink to record
Permanent link

Direct link